Feglymycin, a unique natural bacterial antibiotic peptide, inhibits HIV entry by targeting the viral envelope protein gp120.

[1]  Ron Milo,et al.  Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy , 2011, Nature.

[2]  B. Berkhout,et al.  Resistance of Human Immunodeficiency Virus Type 1 to a Third-Generation Fusion Inhibitor Requires Multiple Mutations in gp41 and Is Accompanied by a Dramatic Loss of gp41 Function , 2011, Journal of Virology.

[3]  G. Doncel,et al.  Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities. , 2010, Antiviral research.

[4]  P. Yeni,et al.  Enfuvirtide: from basic investigations to current clinical use , 2010, Expert opinion on pharmacotherapy.

[5]  N. Dejucq-Rainsford,et al.  Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. , 2010, The Journal of infectious diseases.

[6]  E. Dittmann,et al.  Microvirin, a Novel α(1,2)-Mannose-specific Lectin Isolated from Microcystis aeruginosa, Has Anti-HIV-1 Activity Comparable with That of Cyanovirin-N but a Much Higher Safety Profile* , 2010, The Journal of Biological Chemistry.

[7]  K. Van Laethem,et al.  Actinohivin, a Broadly Neutralizing Prokaryotic Lectin, Inhibits HIV-1 Infection by Specifically Targeting High-Mannose-Type Glycans on the gp120 Envelope , 2010, Antimicrobial Agents and Chemotherapy.

[8]  D. Schols,et al.  The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. , 2009, Antiviral research.

[9]  Tongqing Zhou,et al.  Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment , 2009, Journal of Virology.

[10]  K. Van Laethem,et al.  Human Immunodeficiency Virus Type 1 Escape from Cyclotriazadisulfonamide-Induced CD4-Targeted Entry Inhibition Is Associated with Increased Neutralizing Antibody Susceptibility , 2009, Journal of Virology.

[11]  J. Neyts,et al.  Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. , 2009, Virology.

[12]  D. Schols,et al.  Total synthesis of the antiviral peptide antibiotic feglymycin. , 2009, Angewandte Chemie.

[13]  M. McElrath,et al.  Setting the stage: host invasion by HIV , 2008, Nature Reviews Immunology.

[14]  J. Balzarini,et al.  Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. , 2007, Virology.

[15]  T. Matthews,et al.  Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus , 2007, Proceedings of the National Academy of Sciences.

[16]  Shibo Jiang,et al.  Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion Peptide , 2007, Cell.

[17]  K. Van Laethem,et al.  Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12. , 2007, Virology.

[18]  G. Vanham,et al.  Carbohydrate-Binding Agents Efficiently Prevent Dendritic Cell-Specific Intercellular Adhesion Molecule-3-Grabbing Nonintegrin (DC-SIGN)-Directed HIV-1 Transmission to T Lymphocytes , 2007, Molecular Pharmacology.

[19]  V. KewalRamani,et al.  Dendritic-cell interactions with HIV: infection and viral dissemination , 2006, Nature Reviews Immunology.

[20]  M. Lederman,et al.  Microbicides and other topical strategies to prevent vaginal transmission of HIV , 2006, Nature Reviews Immunology.

[21]  F. Uckun,et al.  Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. , 2006, The Journal of antimicrobial chemotherapy.

[22]  R. Steinman,et al.  Dendritic Cell-Specific Intercellular Adhesion Molecule 3-Grabbing Nonintegrin/CD209 Is Abundant on Macrophages in the Normal Human Lymph Node and Is Not Required for Dendritic Cell Stimulation of the Mixed Leukocyte Reaction1 , 2005, The Journal of Immunology.

[23]  B. Herold,et al.  Candidate Sulfonated and Sulfated Topical Microbicides: Comparison of Anti-Human Immunodeficiency Virus Activities and Mechanisms of Action , 2005, Antimicrobial Agents and Chemotherapy.

[24]  G. Sheldrick,et al.  The antiviral antibiotic feglymycin: first direct-methods solution of a 1000+ equal-atom structure. , 2005, Angewandte Chemie.

[25]  E. De Clercq,et al.  CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro , 2004, AIDS.

[26]  R. Williams,et al.  A novel class of HIV-1 inhibitors that targets the viral envelope and inhibits CD4 receptor binding. , 2004, Current pharmaceutical design.

[27]  E. De Clercq,et al.  Establishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonists , 2004, Retrovirology.

[28]  Michael Greenberg,et al.  Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes , 2004, Nature Reviews Drug Discovery.

[29]  Susan Zolla-Pazner,et al.  Identifying epitopes of HIV-1 that induce protective antibodies , 2004, Nature Reviews Immunology.

[30]  Zheng Yang,et al.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  B. Bray.  Large-scale manufacture of peptide therapeutics by chemical synthesis , 2003, Nature Reviews Drug Discovery.

[32]  R. Elander.  Industrial production of β-lactam antibiotics , 2003, Applied Microbiology and Biotechnology.

[33]  P. Reichelderfer,et al.  Recent observations on HIV type-1 infection in the genital tract of men and women. , 2003, AIDS.

[34]  Douglas S Kwon,et al.  DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells , 2000, Cell.

[35]  W. Aretz,et al.  Feglymycin, a novel inhibitor of the replication of the human immunodeficiency virus. Fermentation, isolation and structure elucidation. , 1999, The Journal of antibiotics.

[36]  J. Sodroski,et al.  Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody , 1998, Nature.

[37]  E. Clercq,et al.  Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4 , 1997, The Journal of experimental medicine.

[38]  L K Pannell,et al.  Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development , 1997, Antimicrobial agents and chemotherapy.

[39]  E. De Clercq,et al.  Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. , 1997, Molecular pharmacology.

[40]  S. Ōmura,et al.  Chloropeptins, new anti-HIV antibiotics inhibiting gp120-CD4 binding from Streptomyces sp. II. Structure elucidation of chloropeptin I. , 1997, The Journal of antibiotics.

[41]  E. De Clercq,et al.  The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication , 1996, Journal of virology.

[42]  M. Hirsch,et al.  Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities , 1996, Antimicrobial agents and chemotherapy.

[43]  R. Colonno,et al.  Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor , 1996, Antimicrobial agents and chemotherapy.

[44]  S. Klohr,et al.  Siamycins I and II, new anti-HIV-1 peptides: II. Sequence analysis and structure determination of siamycin I. , 1995, The Journal of antibiotics.

[45]  S. Hill,et al.  Siamycins I and II, new anti-HIV peptides: I. Fermentation, isolation, biological activity and initial characterization. , 1995, The Journal of antibiotics.

[46]  R. Bruccoleri,et al.  High-resolution solution structure of siamycin II: Novel amphipathic character of a 21-residue peptide that inhibits HIV fusion , 1995, Journal of biomolecular NMR.

[47]  Erik De Clercq,et al.  Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives , 1990, Nature.

[48]  R. Doms,et al.  Entry inhibitors in the treatment of HIV-1 infection. , 2010, Antiviral research.

[49]  Anne-Mieke Vandamme,et al.  A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. , 2005, Journal of virological methods.